We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intersect ENT Inc | NASDAQ:XENT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.25 | 28.16 | 28.36 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
By Colin Kellaher
Medtronic PLC on Friday said it agreed to buy Intersect ENT Inc. in an all-cash deal with an implied enterprise value of about $1.1 billion.
Dublin-based medical-technology company Medtronic said it would pay $28.25 a share for Intersect, a roughly 15.2% premium to Thursday's closing price of $24.52 for the Menlo Park, Calif., ear, nose and throat drug-delivery company.
Medtronic said the deal will expand its portfolio of products used in ear, nose and throat procedures, adding that Intersect's complementary product lines and customer base will bolster its efforts to help patients who suffer from chronic rhinosinusitis.
Medtronic said it expects to complete the acquisition toward the end of its current fiscal year.
Trading in shares of Intersect was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 06, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Intersect ENT Chart |
1 Month Intersect ENT Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
